Effect of nebulised furosemide on breathlessness and cough in interstitial lung disease: a pilot study

Phase 3

• Conditions: Interstitial Lung Disease; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12619001032145
• Lead Sponsor: Hunter New England Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-07-18
• Last Update Posted: 22 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Age > 18 years
Confirmed physician diagnosis of an interstitial lung disease
Medical research council dyspnoea scale of 3-5
Cough visual analogue scale >4cm
FVC >=30% predicted
DLCO >=20% predicted

Exclusion Criteria

Current smoker
Clinical history of asthma or vocal cord dysfunction
Currently pregnant or breastfeeding
Any clinically significant cardiopulmonary abnormalities not related to ILD, including features of congestive cardiac failure on examination or history suggestive of uncontrolled ischaemic heart disease.
Any clinically significant neurological, renal, endocrine, gastrointestinal, hepatic or haematological abnormalities uncontrolled with standard treatment
History of psychiatric, medical or surgical disorders that may interfere with study
Clinical history suggestive of respiratory infection in month preceding study
Alcohol or recreational drug abuse
Inability to understand directions for study assessment, including inability to comprehend English language.
Inability to complete questionnaires required for the study, including visual analogue scales.
Inability to be contacted in case of emergency
Participation in another study at the same time or within a prior 3-month period
Regular use of short or long-acting opioids, pregabalin or gabapentin.
Inability to complete a 6 minute walk test
Allergy or significant adverse reaction to furosemide

Study & Design

• Study Type: Interventional
• Study Design: Not specified